Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

Publication | Closed Access

DOI

100

Citations

References

2009

Year

Jeffrey S. Berger, Matthew T. Roe, C. Michael Gibson, Rakhi Kilaru, Cynthia L. Green, Laura G. Melton, James Blankenship, D. Christopher Metzger, Christopher B. Granger, Daniel D. Gretler,

American Heart Journal

ThrombosisPercutaneous Coronary InterventionPlatelet ThrombosisCardiovascular DiseaseBlood PlateletIntravenous ElinogrelPharmacotherapyPlatelet AntagonistMedicineAnticoagulantCardiologyEmergency MedicineAcute Myocardial InfarctionMyocardial Infarction